Promising Developments in Stoke Therapeutics’ Clinical Trials Support Buy Rating

Ananda Ghosh, an analyst from H.C. Wainwright, maintained the Buy rating on Stoke Therapeutics. The associated price target remains the same with $35.00.

Ananda Ghosh’s rating is based on several promising developments in Stoke Therapeutics’ clinical trials. The initiation of the Phase 3 EMPEROR study marks a significant step in the development of zorevunersen, with sites already active in multiple countries and plans for further expansion. The 36-month open-label extension data has shown a continued reduction in convulsive seizures and improvements in various cognitive and behavioral domains, as measured by the Vineland-3 scores. These results suggest long-term disease modification potential, which is crucial for addressing unmet needs in Dravet syndrome.
Ananda Ghosh also highlights the importance of these cognitive and behavioral improvements, which are not adequately addressed by current therapies. The potential for zorevunersen to meet these needs could lead to a differentiated value proposition for stakeholders if the results are replicated in the pivotal trial. Additionally, Stoke’s expansion into ocular genetics with STK-002 provides a second clinical asset, further validating the company’s platform potential. These factors collectively support the Buy rating for Stoke Therapeutics’ stock.

In another report released today, Chardan Capital also reiterated a Buy rating on the stock with a $24.00 price target.

Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of STOK in relation to earlier this year.